Rocaltrol Related Published Studies
Well-designed clinical trials related to Rocaltrol (Calcitriol)
Calcium balance during calcitriol and paricalcitol administration in healthy humans. [2008.03]
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. [2008.01.15]
Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial. [2008.01]
Comparison of cutaneous tolerance and efficacy of calcitriol 3 mug g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. [2007.11]
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. [2007.02.20]
Effects of a combined alendronate and calcitriol agent (Maxmarvil(R)) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. [2006.12]
Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure. [2006.11]
High dose calcitriol may reduce thrombosis in cancer patients. [2006.11]
Calcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: a double-blind placebo-controlled trial. [2006.10]
Calcitriol in the treatment of prostate cancer. [2006.07]
Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents. [2005.11]
Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients. [2005.09]
Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy. [2005.09]
ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. [2005.09]
Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. [2005.05]
Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. [2005.02]
Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism. [2004.12]
Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. [2004.12]
The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis. [2004.11]
Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. [2004.10.27]
Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. [2004.08]
The effects of calcitriol on falls and fractures and physical performance tests. [2004.05]
Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. [2004.04]
Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. [2004.04]
Calcitriol in cancer treatment: from the lab to the clinic. [2004.03]
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. [2004.02.19]
Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. [2004.02]
Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. [2003.11.27]
Comparative efficacy of oral and intravenous calcitriol treatment in haemodialysis patients: effects on serum biochemistry and cytokine levels. [2003.11]
Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. [2003.09]
A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density. [2003.07]
Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol. [2003.06.27]
Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis. [2003.06]
Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis. [2003.05]
Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. [2003.05]
Growth in children with chronic renal failure on intermittent versus daily calcitriol. [2003.05]
Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate. [2003.04]
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. [2003.04]
Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. [2003.02]
Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. [2003.01]
Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. [2002.11]
Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses. [2002.04]
The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. [2002.02.27]
Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density. [2002.02]
Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. [2001.11]
Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study. [2001.09]
Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. [2001.08]
The safety of calcitriol 3 microg/g ointment. Evaluation of cutaneous contact sensitization, cumulative irritancy, photoallergic contact sensitization and phototoxicity. [2001.05]
Clinical experience with topical calcitriol (1,25-dihydroxyvitamin D3) in psoriasis. [2001.04]
Efficacy and tolerance of topical calcitriol 3 microg g(-1) in psoriasis treatment: a review of our experience in Poland. [2001.04]
Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. [2001.03]
Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. [2001.03]
Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. [2000.12]
Calcitriol per os once, twice or three times a week: effect of different schedules of administration in hemodialysis patients. [2000.11]
A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients. [2000.10]
Effect of calcitriol on bone loss after cardiac or lung transplantation. [2000.09]
Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. [2000.08]
Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study. [2000.07]
Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure. [2000.07]
Changes in bone turnover after parathyroidectomy in dialysis patients: role of calcitriol administration. [2000.06]
Twice versus thrice weekly administration of intravenous calcitriol in dialysis patients: a randomized prospective trial. Gruppo Italiano di Studio dell'Osteodistrofia Renale. [2000.03]
Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen. [2000.02.15]
A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial. [2000]
The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. [2000]
Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients. [2000]
Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women. [2000]
Calcium absorption in postmenopausal osteoporosis: benefit of HRT plus calcitriol, but not HRT alone, in both malabsorbers and normal absorbers. [2000]
Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy. [1999.12]
Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. [1999.08.27]
Calcitriol for bone disease in patients with cirrhosis of the liver. [1999.06]
Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers. [1999.04.09]
A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. [1999.04]
Calcitriol for bone loss in patients with primary biliary cirrhosis. [1999.04]
Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men. [1998.09]
Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. [1998.09]
Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. [1998.06]
Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. [1998.05]
Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure. [1998.04]
No effect of calcitriol on insulin-mediated glucose uptake in healthy subjects. [1997.07]
Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study. [1997.07]
A randomized double-blind comparison of the effects on systemic calcium homeostasis of topical calcitriol (3 micrograms/g) and calcipotriol (50 micrograms/g) in the treatment of chronic plaque psoriasis vulgaris. [1997.05]
'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study. [1997]
Effects of calcitriol on eosinophil activity and antibody responses in patients with schistosomiasis. [1997]
Effect of UVB phototherapy and oral calcitriol (1,25-dihydroxyvitamin D3) on vitamin D photosynthesis in patients with psoriasis. [1996.11]
Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. [1996.08.28]
Dose-response effect of short-term calcitriol treatment on bone and mineral metabolism in normal males. [1996.06]
Predialysis calcitriol administration: effects on pre- and post-transplant renal osteodystrophy. [1996.06]
Calcitriol and the parathyroid hormone-ionized calcium curve: a comparison of methodologic approaches. [1996.03]
Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. [1996.03]
Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin d3) for the treatment of psoriasis. [1996.02]
Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). [1995.12]
Oestrogen effects on calcitriol levels in post-menopausal women: a comparison of oral versus transdermal administration. [1995.08]
Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure. [1995]
Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism. [1995]
Calcitriol. A review of its use in the treatment of postmenopausal osteoporosis and its potential in corticosteroid-induced osteoporosis. [1994.10]
Topically applied low-dose calcitriol has no calciotropic effect in patients with stable plaque psoriasis. [1994.06]
Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. [1994.06]
A prospective, double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol. The Growth Failure in Children with Renal Diseases Investigators. [1994.04]
Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. [1994]
Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. [1994]
Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. [1993.10]
|
